Brain Tumours

Conclusions • MEK inhibitors are exciting new agents for low grade gliomas. • Imaging responses can be documented after prolonged exposure to therapy (4-6 months) • BRAF V600E specific inhibitors being tested in low-grade and high-grade gliomas; responses have been observed in patients with progressive disease • Phase I/II studies ongoing with mTOR inhibitors, BRAF V600E inhibitors; MEK inhibitors and combination of BRAF inhibitors and MEK inhibitors • New paradigm for treatment of LGG that uses tumor biology to direct therapy